Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper

Abstract

Background and objectives:

Treatment of spasticity poses a major challenge given the complex clinical presentation and variable efficacy and safety profiles of available drugs. We present a systematic review of the pharmacological treatment of spasticity in multiple sclerosis (MS) patients.

Methods:

Controlled trials and observational studies were identified. Scientific evidence was evaluated according to pre-specified levels of certainty.

Results:

The evidence supports the use of baclofen, tizanidine and gabapentin as first-line options. Diazepam or dantrolene could be considered if no clinical improvement is seen with the previous drugs. Nabiximols has a positive effect when used as add-on therapy in patients with poor response and/or tolerance to first-line oral treatments. Despite limited evidence, intrathecal baclofen and intrathecal phenol show a positive effect in severe spasticity and suboptimal response to oral drugs.

Conclusion:

The available studies on spasticity treatment offer some insight to guide clinical practice but are of variable methodological quality. Large, well-designed trials are needed to confirm the effectiveness of antispasticity agents and to produce evidence-based treatment algorithms.

Keywords

Multiple sclerosis spasticity pharmacological treatment review

Get full access to this article

View all access options for this article.

References

Rizzo

Hadjimichael

Preiningerova

. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004; 10: 589–595.

Biering-Sorensen

Nielsen

Klinge

. Spasticity-assessment: A review. Spinal Cord 2006; 44: 708–722.

Haselkorn

Balsdon

Fry

. Overview of spasticity management in multiple sclerosis: Evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med 2005; 28: 167–199.

Platz

Eickhof

Nuyens

. Clinical scales for the assessment of spasticity, associated phenomena, and function: A systematic review of the literature. Disabil Rehabil 2005; 27: 7–18.

Haugh

Pandyan

Johnson

. A systematic review of the Tardieu Scale for the measurement of spasticity. Disabil Rehabil 2006; 28: 899–907.

Priebe

Sherwood

Thornby

. Clinical assessment of spasticity in spinal cord injury: A multidimensional problem. Arch Phys Med Rehabil 1996; 77: 713–716.

Hobart

Riazi

Thompson

. Getting the measure of spasticity in multiple sclerosis: The Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 2006; 129: 224–234.

Syczewska

Lebiedowska

Pandyan

. Quantifying repeatability of the Wartenberg pendulum test parameters in children with spasticity. J Neurosci Methods 2009; 178: 340–344.

Thompson

Jarrett

Lockley

. Clinical management of spasticity. J Neurol Neurosurg Psychiatry 2005; 76: 459–463.

10.

Lapeyre

Kuks

Meijler

. Spasticity: Revisiting the role and the individual value of several pharmacological treatments. NeuroRehabilitation 2010; 27: 193–200.

11.

Amatya

Khan

La Mantia

. Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database Syst Rev 2013; 2: CD009974.

12.

Brainin

Barnes

Baron

. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – Revised recommendations 2004. Eur J Neurol 2004; 11: 577–581.

13.

Summary of product characteristics: Oral baclofen, http://www.medicines.org.uk/emc/medicine/23850 (accessed December 2015).

14.

Basmajian

. Lioresal (baclofen) treatment of spasticity in multiple sclerosis. Am J Phys Med 1975; 54: 175–177.

15.

Jerusalem

. Double-blind study on the antispastic effect of beta-94-chlorphenyl)-gamma aminobutyric acid (CIBA) in multiple sclerosis. Nervenarzt 1968; 39: 515–517 (in German).

16.

Brar

Smith

Nelson

. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch Phys Med Rehabil 1991; 72: 186–189.

17.

Cartlidge

Hudgson

Weightman

. A comparison of baclofen and diazepam in the treatment of spasticity. J Neurol Sci 1974; 23: 17–24.

18.

Feldman

Kelly-Hayes

Conomy

. Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. Neurology 1978; 28: 1094–1098.

19.

From

Heltberg

. A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand 1975; 51: 158–166.

20.

Hudgson

Weightman

. Baclofen in the treatment of spasticity. Br Med J 1971; 4: 15–17.

21.

Orsnes

Sorensen

Larsen

. Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand 2000; 101: 244–248.

22.

Roussan

Terrence

Fromm

. Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy. Pharmatherapeutica 1985; 4: 278–284.

23.

Sachais

Logue

Carey

. Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Arch Neurol 1977; 34: 422–428.

24.

Sawa

Paty

. The use of baclofen in treatment of spasticity in multiple sclerosis. Can J Neurol Sci 1979; 6: 351–354.

25.

Levine

Jossmann

DeAngelis

. Liorseal, a new muscle relaxant in the treatment of spasticity – A double-blind quantitative evaluation. Dis Nerv Syst 1977; 38: 1011–1015.

26.

Dario

Tomei

. A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf 2004; 27: 799–818.

27.

Summary of product characteristics: Tizanidine, https://www.medicines.org.uk/emc/medicine/22602 (accessed December 2015).

28.

Emre

Leslie

Muir

. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). J Neurol Neurosurg Psychiatry 1994; 57: 1355–1359.

29.

Nance

Sheremata

Lynch

. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol 1997; 54: 731–736.

30.

Vakhapova

Auriel

Karni

. Nightly sublingual tizanidine HCl in multiple sclerosis: Clinical efficacy and safety. Clin Neuropharmacol 2010; 33: 151–154.

31.

Smith

Birnbaum

Carter

. Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology 1994; 44: S34–S42.

32.

Lapierre

Bouchard

Tansey

. Treatment of spasticity with tizanidine in multiple sclerosis. Can J Neurol Sci 1987; 14: 513–517.

33.

A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. Neurology 1994; 44: S70–S78.

34.

Rinne

. Tizanidine treatment of spasticity in multiple sclerosis and chronic myelopathy. Curr Ther Res Clin Exp 1980; 28: 827–836.

35.

Eyssette

Rohmer

Serratrice

. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin 1988; 10: 699–708.

36.

Hoogstraten

van der Ploeg

. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta Neurol Scand 1988; 77: 224–230.

37.

Newman

Nogues

Newman

. Tizanidine in the treatment of spasticity. Eur J Clin Pharmacol 1982; 23: 31–35.

38.

Rice

GP.

Tizanidine

. baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1989; 16: 451.

39.

Smolenski

Muff

Smolenski-Kautz

. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103–282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin 1981; 7: 374–383.

40.

Stien

Nordal

Oftedal

. The treatment of spasticity in multiple sclerosis: A double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. Acta Neurol Scand 1987; 75: 190–194.

41.

Wagstaff

Bryson

. Tizanidine: A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997; 53: 435–452.

42.

Neill

. Diazepam in the relief of muscle spasm resulting from spinal-cord lesions. Ann Phys Med 1964; (Suppl 1): 33–38.

43.

Schmidt

Lee

Spehlmann

. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psychiatry 1976; 39: 350–356.

44.

Basmajian

Shankardass

Russell

. Ketazolam treatment for spasticity: Double-blind study of a new drug. Arch Phys Med Rehabil 1984; 65: 698–701.

45.

Basmajian

Shankardass

Russell

. Ketazolam once daily for spasticity: Double-blind cross-over study. Arch Phys Med Rehabil 1986; 67: 556–557.

46.

Kita

Goodkin

. Drugs used to treat spasticity. Drugs 2000; 59: 487–495.

47.

Solaro

Lunardi

Capello

. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology 1998; 51: 609–611.

48.

Solaro

Uccelli

Guglieri

. Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Mult Scler 2000; 6: 192–193.

49.

Dunevsky

Perel

. Gabapentin for relief of spasticity associated with multiple sclerosis. Am J Phys Med Rehabil 1998; 77: 451–454.

50.

Cutter

Scott

Johnson

. Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000; 81: 164–169.

51.

Mueller

Gruenthal

Olson

. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil 1997; 78: 521–524.

52.

Kamen

Henney

III Runyan

. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin 2008; 24: 425–439.

53.

Clinical practice guideline on the management of people with multiple sclerosis . Barcelona: Catalan Health Agency for Quality and Assessment (AQuAS); Multiple Sclerosis Center of Catalonia (Cemcat); Departament de Salut, Generalitat de Catalunya, 2012.

54.

Summary of product characteristics: Dantrolene, https://www.medicines.org.uk/emc/medicine/24339 (accessed December 2015).

55.

Ladd

Oist

Jonsson

. The effect of Dantrium on spasticity in multiple sclerosis. Acta Neurol Scand 1974; 50: 397–408.

56.

Gambi

Rossini

Calenda

. Dantrolene sodium in the treatment of spasticity caused by multiple sclerosis or degenerative myelopathies: A double-blind, crossover study in comparison with placebo. Curr TherRes Clin Exp 1983; 33: 835–840.

57.

Sheplan

Ishmael

. Spasmolytic properties of dantrolene sodium: Clinical evaluation. Mil Med 1975; 140: 26–29.

58.

Gelenberg

Poskanzer

. The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology 1973; 23: 1313–1315.

59.

Tolosa

Soll

Loewenson

. Letter: Treatment of spasticity in multiple sclerosis with dantrolene. JAMA 1975; 233: 1046.

60.

Pinder

Brogden

Speight

. Dantrolene sodium: A review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1977; 13: 3–23.

61.

Russo

Guy

. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006; 66: 234–246.

62.

Meinck

Schonle

Conrad

. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989; 236: 120–122.

63.

Wade

Makela

House

. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12: 639–645.

64.

Wade

Robson

House

. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21–29.

65.

Wissel

Haydn

Muller

. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial. J Neurol 2006; 253: 1337–1341.

66.

Collin

Davies

Mutiboko

. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007; 14: 290–296.

67.

Killestein

Hoogervorst

Reif

. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404–1407.

68.

Notcutt

Langford

Davies

. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(^®) (nabiximols). Mult Scler 2012; 18: 219–228.

69.

Novotna

Mares

Ratcliffe

. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(^®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; 18: 1122–1131.

70.

Vaney

Heinzel-Gutenbrunner

Jobin

. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004; 10: 417–424.

71.

Wade

Makela

Robson

. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10: 434–441.

72.

Zajicek

Fox

Sanders

. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517–1526.

73.

Zajicek

Sanders

Wright

. Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1664–1669.

74.

Wade

Collin

Stott

. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010; 16: 707–714.

75.

Karst

Wippermann

Ahrens

. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 2010; 70: 2409–2438.

76.

Farrar

Troxel

Stott

. Validity, reliability, and clinical importance of change in a 0–10 numeric rating scale measure of spasticity: A post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008; 30: 974–985.

77.

Fleuren

Voerman

Erren-Wolters

. Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry 2010; 81: 46–52.

78.

Wang

Collet

Shapiro

. Adverse effects of medical cannabinoids: A systematic review. CMAJ 2008; 178: 1669–1678.

79.

National Clinical Guideline Centre. Multiple sclerosis: Management of multiple sclerosis in primary and secondary care. London: National Institute for Health and Care Excellence, 2014.

80.

Pathak

Nguyen

Graham

. Management of spasticity in adults: Practical application of botulinum toxin. Eur J Neurol 2006; 13(Suppl. 1): 42–50.

81.

Borg-Stein

Pine

Miller

. Botulinum toxin for the treatment of spasticity in multiple sclerosis. New observations. Am J Phys Med Rehabil 1993; 72: 364–368.

82.

Grazko

Polo

Jabbari

. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995; 45: 712–717.

83.

Finsterer

Fuchs

Mamoli

. Automatic EMG-guided botulinum toxin treatment of spasticity. Clin Neuropharmacol 1997; 20: 195–203.

84.

Snow

Tsui

Bhatt

. Treatment of spasticity with botulinum toxin: A double-blind study. Ann Neurol 1990; 28: 512–515.

85.

Hyman

Barnes

Bhakta

. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: A prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000; 68: 707–712.

86.

Wood

. The use of phenol as a neurolytic agent: A review. Pain 1978; 5: 205–229.

87.

Copp

Harris

Keenan

. Peripheral nerve block and motor point block with phenol in the management of spasticity. Proc R Soc Med 1970; 63: 937–938.

88.

Wassef

. Interadductor approach to obturator nerve blockade for spastic conditions of adductor thigh muscles. Reg Anesth 1993; 18: 13–17.

89.

Awad

. Phenol block for control of hip flexor and adductor spasticity. Arch Phys Med Rehabil 1972; 53: 554–557.

90.

Akkaya

Unlu

Alptekin

. Neurolytic phenol blockade of the obturator nerve for severe adductor spasticity. Acta Anaesthesiol Scand 2010; 54: 79–85.

91.

Coffey

Cahill

Steers

. Intrathecal baclofen for intractable spasticity of spinal origin: Results of a long-term multicenter study. J Neurosurg 1993; 78: 226–232.

92.

Middel

Kuipers-Upmeijer

Bouma

. Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 1997; 63: 204–209.

93.

Penn

Savoy

Corcos

. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320: 1517–1521.

94.

Penn

. Intrathecal baclofen for spasticity of spinal origin: Seven years of experience. J Neurosurg 1992; 77: 236–240.

95.

Intrathecal baclofen pump for spasticity: An evidence-based analysis. Ont Health Technol Assess Ser 2005; 5: 1–93.

96.

Browne

Catton

. The use of intrathecal phenol for muscle spasms in multiple sclerosis. A description of two cases. Can Anaesth Soc J 1975; 22: 208–218.

97.

Cain

. Subarachnoid phenol block in the treatment of pain and spasticity. Paraplegia 1965; 3: 152–160.

98.

Jarrett

Nandi

Thompson

. Managing severe lower limb spasticity in multiple sclerosis: Does intrathecal phenol have a role? J Neurol Neurosurg Psychiatry 2002; 73: 705–709.

99.

Pinder

Bhakta

Kodavali

. Intrathecal phenol: An old treatment revisited. Disabil Rehabil 2008; 30: 381–386.